A Convergent fabrication of silk fibroin nanoparticles on quercetin loaded metal-organic frameworks for promising nanocarrier of myocardial infraction

Junjun Hao; Ankang Lv; Xingsheng Li; Yongyong Li

doi:10.1016/j.heliyon.2023.e20746

A Convergent fabrication of silk fibroin nanoparticles on quercetin loaded metal-organic frameworks for promising nanocarrier of myocardial infraction

Heliyon. 2023 Oct 6;9(10):e20746. doi: 10.1016/j.heliyon.2023.e20746. eCollection 2023 Oct.

Authors

Junjun Hao¹, Ankang Lv², Xingsheng Li², Yongyong Li²

Affiliations

¹ Department of Cardiovascular Surgery, First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an-710061, China.
² Department of Gerontology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing-400010, China.

Abstract

The biomacromolecule silk fibroin (SF) may be constructed to promote biomimetic nucleation and nanostructures of inorganic nanomaterials, offering it a promising candidate for use in various biomimetic applications. We combined SF-NPs and ZIF-8-NPs to fabricate new drug vehicles that effectively release the drug. SF nanoparticles (SF-NPs) were assembled into quercetin (QCT), a myocardial drug added to fabricate QSF-NPs. By acting as a template for the ZIF-8 nucleation onto the surface, the QSF-NPs fabricated core-shell-structured nanocomposites (named QSF@Z-NCs) with ZIF-8 as the core-shell and the QSF-NPs. The biocompatibility analysis using the MTT assay revealed that the developed QCT, SF-NPs, and QSF@Z-NCs are not harmful to cardiac myoblast (H9C2) cells. The in vivo model demonstrated that H9C2 cells encouraged cardiomyocyte fibre regeneration in myocardial infarction rats. We fabricated a brand-new technique using H9C2 cells and QSF@Z-NCs that might encourage the healing processes in myocardial ischemia cells. This study's results demonstrate that it successfully treats myocardial injury.

Keywords: Drug delivery; Myocardial infraction; Silk fibroin; Zeolitic imidazolate framework-8 (ZIF-8); pH-responsive.